A new clinical and preclinical study from UCLA Jonsson Comprehensive Cancer Center identifies the DNA roots of resistance to targeted cancer therapy. Results are published online ahead of print in Cancer Discovery, a journal of the American Association for Cancer Research.
Investigators at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have shown for the first time that a combination of targeted therapies with immunotherapy addresses a major cause of treatment resistance in pancreatic cancer.
A study, led by researchers at the Johns Hopkins Kimmel Cancer Center, that analyzed the tumor microenvironment of pancreatic cancer revealed the cause of tumor cell resistance to immunotherapy and resulted in new treatment strategies.
Investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that a subset of mutations within the overall tumor mutation burden, termed “persistent mutations,” are less likely to be edited out as cancer evolves, rendering tumors continuously visible to the immune system and predisposing them to respond to immunotherapy.
Inhibiting a particular protein in cancer-killing immune cells might improve the long-term effectiveness of CAR T cell and other immune checkpoint therapies, according to a study by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
A study by researchers at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute suggests a way to re-energize critical killer immune cells that have become exhausted when fighting cancer or chronic viral infections.
Moffitt Cancer Center researchers, led by cancer biologist Eric Lau, demonstrated how L-fucose, a nontoxic dietary plant sugar that is enriched in red and brown seaweeds, can increase tumor infiltrating lymphocytes, promote antitumor immunity, and improve the efficacy of immunotherapy.
FDA approved Keytruda (pembrolizumab) for adjuvant treatment following resection and platinum-based chemotherapy for stage 1B, 2, or 3A non-small cell lung cancer.
FDA approved Brukinsa (zanubrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma.
Thermo Fisher Scientific and AstraZeneca formed a global, multiyear agreement to develop a solid tissue and blood-based companion diagnostic test for Tagrisso (osimertinib).
